Lakefront Biotherapeutics (LKFT) earnings history
Most recent quarter
- Fiscal period
- Q1 2026
- Period end
- Mar 31, 2026
- EPS actual
- $0.25
- EPS estimate
- −$0.94
- EPS surprise
- +126.32%
- Revenue surprise
- −77.47%
- Revenue
- $7.6M
- Revenue estimate
- $33.9M
- Reported
- May 6, 2026
Lakefront Biotherapeutics' latest results are for Q1 2026, reported on May 6, 2026. Earnings per share were $0.25 against an expected loss of $0.94, a beat of 126.32%. Revenue was $7.6 million, 77.47% below the $33.9 million consensus. Compared with Q1 2025, the result swung from a loss of $2.67 per share to a profit, while revenue fell about 91% from $85.3 million.
The history is irregular. Q4 2025 shows EPS of $13.90 and revenue of $1.0 billion against an $82.9 million estimate, far outside every other quarter, where revenue ranged from $65.0 million to $206.9 million. The table also has no Q4 2023 row, and Q2 2024 has no valid report date. Ten of the 20 quarters shown were losses, including Q1 to Q3 2025. Annual revenue fell from $626.5 million in 2021 to $297.7 million in 2024, and Q1 2026 was the lowest quarter here.
Q2 results came out between July 24 and August 8 in past years, and no Q2 2026 row appears in the table yet. When it arrives, it will show whether revenue recovers from the Q1 level and whether the return to profit holds.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q1 2026 | May 6, 2026 | −$0.94 | $0.25 | +126.32% | $7.6M | SEC |
| Q4 2025 | Feb 23, 2026 | −$0.13 | $13.90 | +11088.22% | $1.0B | SEC |
| Q3 2025 | Nov 6, 2025 | −$0.48 | −$3.54 | −641.44% | $82.1M | SEC |
| Q2 2025 | Jul 24, 2025 | −$0.23 | −$1.85 | −711.65% | $76.8M | SEC |
| Q1 2025 | Apr 23, 2025 | −$0.14 | −$2.67 | −1783.58% | $85.3M | SEC |
| Q4 2024 | Feb 12, 2025 | −$0.55 | $0.30 | +155.11% | $79.3M | SEC |
| Q3 2024 | Oct 31, 2024 | −$0.17 | −$0.80 | −374.54% | $65.0M | SEC |
| Q2 2024 | Invalid Date | −$0.07 | $0.08 | +205.53% | $86.2M | — |
| Q1 2024 | May 3, 2024 | −$0.08 | $0.39 | +561.43% | $67.2M | SEC |
| Q3 2023 | Nov 3, 2023 | −$1.13 | $0.42 | +137.19% | $128.9M | SEC |
| Q2 2023 | Aug 4, 2023 | −$0.82 | $0.09 | +110.79% | $165.3M | SEC |
| Q1 2023 | May 5, 2023 | −$0.96 | $0.39 | +140.15% | $196.9M | SEC |
| Q4 2022 | Feb 24, 2023 | −$0.65 | −$3.32 | −412.36% | $100.5M | SEC |
| Q3 2022 | Nov 7, 2022 | −$0.81 | $0.33 | +140.51% | $135.6M | — |
| Q2 2022 | Aug 8, 2022 | −$0.68 | −$0.29 | +56.70% | $140.1M | — |
| Q1 2022 | May 6, 2022 | −$0.68 | −$0.21 | +68.70% | $144.2M | — |
| Q4 2021 | Mar 24, 2022 | −$1.04 | $0.28 | +126.93% | $206.9M | — |
| Q3 2021 | Nov 8, 2021 | −$1.70 | −$1.14 | +32.77% | $88.9M | — |
| Q2 2021 | Aug 5, 2021 | −$1.44 | −$1.15 | +19.89% | $179.9M | — |
| Q1 2021 | May 11, 2021 | −$1.12 | −$0.23 | +79.35% | $150.8M | — |
Quarterly revenue
Frequently asked questions
When did Lakefront Biotherapeutics (LKFT) last report earnings?
Lakefront Biotherapeutics last reported on May 6, 2026, covering fiscal Q1 2026.
Did LKFT beat earnings estimates?
Yes. Lakefront Biotherapeutics reported EPS of $0.25 for Q1 2026 against a −$0.94 estimate — a 126.32% beat.
How much revenue did LKFT report last quarter?
Lakefront Biotherapeutics reported $7.6M in revenue for Q1 2026, against a consensus estimate of $33.9M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.